Skip to main content
Quest Diagnostics

Treatment of BOLA3-Associated Multiple Mitochondrial Dysfunctions Syndrome 2 with a Mitochondrial Cocktail

ACMG Annual Clinical Genetics meeting 2025

American College of Medical Genetics

Los Angeles, CA, Mar 18-21 , 2025

Poster presentation: Treatment of BOLA3-Associated Multiple Mitochondrial Dysfunctions Syndrome 2 with a Mitochondrial Cocktail

Authors: Peretz RH, Tanpaiboon P

Specialty: Genetics, Neurology, Pediatrics

Related content

Conference Presentation
A retrospective review of mitochondrial genome NGS analysis in 7000 rare disease patients
Conference Presentation
Limit of Detection and Effect on Performance of Sample Cross Contamination of NGS Libraries With Mitochondrial DNA
Conference Presentation
Evaluation of population frequency data for mitochondrial variant interpretation
Audio Podcast
Patient-minded Neurology
Publication
Infantile-Onset Charcot-Marie-Tooth Disease With Pyramidal Features and White Matter Abnormalities Due to a De novo MORC2 Gene Variant: A Case Report and Brief Review of the Literature

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.